​The Age of Cell Replacement Has Begun.

​On February 19, 2026, Japan approved the first iPSC-derived therapies for heart failure and Parkinson’s disease.

​The question is no longer whether this can work.

​The focus now is on how quickly these medicines will be scaled, who will gain access, and what they will enable in the next decade.

​Join Cellino co-founders Nabiha Saklayen and Marinna Madrid as they discuss what made this moment possible and what comes next, moderated by neurosurgeon Achal Singh Achrol.

​About Cellino

​Cellino is shaping the future of regenerative health by manufacturing patient-specific, iPSC-derived therapies at scale. Its platform has received the FDA designation for an Advanced Manufacturing Technology.

​About Nabiha Saklayen

​Nabiha is co-founder and CEO of Cellino, a member of the National Academies Forum on Regenerative Medicine, and was named Ernst & Young Entrepreneur of the Year 2025. She holds a PhD in Physics from Harvard and was the inaugural Tory Burch Foundation Fellow with Jennifer Doudna.

​About Marinna Madrid

​Marinna is co-founder and CPRO (Chief Product & Regulatory Officer) at Cellino, leading regulatory strategy, including its FDA Advanced Manufacturing Technology designation. She is a Forbes 30 Under 30 honoree, with multiple patents and publications, and holds a PhD in Applied Physics from Harvard.

​About Achal Singh Achrol

​A Stanford-trained neurosurgeon and physician-executive working on scalable health technology platforms across devices, therapeutics, AI, and data to translate frontier science into real-world clinical impact. He currently serves as Chief Medical Officer at Magnus Medical and Bionaut Labs.